Vasopressin-2 receptor antagonists in autosomal dominant polycystic kidney disease: from man to mouse and back

被引：5
|
作者：
Devuyst, Olivier [1 ,2 ]
Wang, Xueqi [1 ,3 ]
Serra, Andreas [1 ,2 ]
机构：
[1] Univ Zurich, Div Nephrol, Univ Spital, Zurich, Switzerland
[2] Univ Zurich, Inst Physiol, Zurich, Switzerland
[3] Second Mil Med Univ, Dept Nephrol, Shanghai Changzheng Hosp, Shanghai, Peoples R China
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2011年 / 26卷 / 08期
关键词：
ADPKD; PKD1; renal cysts; Tolvaptan; EXPRESSION; PKD1; VARIABILITY; PROGRESSION; GROWTH; MICE; RAT;
D O I：
10.1093/ndt/gfr380
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
引用
收藏
页码：2423 / 2425
页数：3
相关论文
共 50 条
  • [1] Vasopressin-2 Receptor Signaling and Autosomal Dominant Polycystic Kidney Disease: From Bench to Bedside and Back Again
    Rinschen, Markus M.
    Schermer, Bernhard
    Benzing, Thomas
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2014, 25 (06): : 1140 - 1147
  • [2] Will vasopressin 2 receptor antagonists prevent autosomal dominant polycystic kidney disease?
    不详
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (01): : 6 - 7
  • [3] Vasopressin V2 receptor antagonists in autosomal dominant polycystic kidney disease: efficacy, safety, and tolerability
    Meijer, Esther
    Gansevoort, Ron T.
    KIDNEY INTERNATIONAL, 2020, 98 (02) : 289 - 293
  • [4] Concurrent Targeting of Vasopressin Receptor 2 and Somatostatin Receptors in Autosomal Dominant Polycystic Kidney Disease: A Promising Approach for Autosomal Dominant Polycystic Kidney Disease Treatment?
    Hogan, Marie C.
    Masyuk, Tatyana V.
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (02): : 154 - 156
  • [5] A defect in vasopressin secretion in autosomal dominant polycystic kidney disease
    Bichet, Daniel G.
    KIDNEY INTERNATIONAL, 2012, 82 (10) : 1051 - 1053
  • [6] Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease
    Devuyst, Olivier
    Torres, Vicente E.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2013, 22 (04): : 459 - 470
  • [7] Benzodiazepine Derivatives as Potent Vasopressin V2 Receptor Antagonists for the Treatment of Autosomal Dominant Kidney Disease
    Cao, Xudong
    Wang, Peng
    Yuan, Haoxing
    Zhang, Haoran
    He, Yan
    Fu, Kequan
    Fang, Qian
    Liu, Hongli
    Su, Limin
    Yin, Long
    Xu, Pei
    Xie, Yuyang
    Xiong, Xiaochun
    Wang, Junqi
    Zhu, Xu
    Guo, Dong
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, : 9295 - 9311
  • [8] Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease
    Zittema, Debbie
    Versteeg, Irina B.
    Gansevoort, Ron T.
    van Goor, Harry
    de Heer, Emile
    Veraar, Kimberley A. M.
    Peters, Dorien J. M.
    Meijer, Esther
    AMERICAN JOURNAL OF NEPHROLOGY, 2016, 44 (03) : 194 - 203
  • [9] Vasopressin Receptor Antagonists, Heart Failure, and Polycystic Kidney Disease
    Torres, Vicente E.
    ANNUAL REVIEW OF MEDICINE, VOL 66, 2015, 66 : 195 - 210
  • [10] Vasopressin antagonists in polycystic kidney disease
    Torres, VE
    KIDNEY INTERNATIONAL, 2005, 68 (05) : 2405 - 2418
12345